title: Genetic analysis of familial hypercholesterolaemia in Western Australia.
abstract: OBJECTIVE
  To determine the spectrum of mutations associated with familial hypercholesterolaemia (FH) and their detection rate in the FH Western Australia (FHWA) Program.
  
  
  METHODS
  Mutation testing of the LDLR gene, plus select regions in APOB and PCSK9, was performed in the first 343 patients considered to be phenotypic index cases of FH and classified on the basis of the Dutch Lipid Clinic Network Criteria (DLCNC) score as "possible", "probable", or "definite" FH.
  
  
  RESULTS
  Overall, 86 different pathogenic (or likely pathogenic) mutations were identified in 129 patients, including four compound heterozygotes manifesting a more severe clinical phenotype. Fourteen of these mutations were novel and twelve (9.6%) were large deletions/duplications of the LDLR. The most common mutations were the familial defective apoB-100 mutation APOB p.Arg3527Gln (7.2%) and an LDLR intron 3 splice site mutation c.313 + 1G > A (4.8%). While 70% of 'definite' FH patients were found to carry a mutation, only 29% of 'probable' and 11% of 'possible' FH patients were mutation-positive.
  
  
  CONCLUSIONS
  This information provides a useful DNA database on which to base ongoing cascade screening for FH and future research into the genetic aetiology of FH in Western Australia. These findings suggest genetic testing should be prioritised to those with high DLCNC scores and offers a cost-effective family screening method from FH index cases, leading to detection of other previously undiagnosed and younger family members, enabling early instigation of intervention and preventative measures for premature coronary heart disease.
authors.affiliation: Cardiovascular Genetics Laboratory, Department of Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Australia.
authors.forename: Amanda J
authors.initials: AJ
authors.lastname: Hooper
authors.forename: Lan T
authors.initials: LT
authors.lastname: Nguyen
authors.forename: John R
authors.initials: JR
authors.lastname: Burnett
authors.forename: Timothy R
authors.initials: TR
authors.lastname: Bates
authors.forename: Damon A
authors.initials: DA
authors.lastname: Bell
authors.forename: Trevor G
authors.initials: TG
authors.lastname: Redgrave
authors.forename: Gerald F
authors.initials: GF
authors.lastname: Watts
authors.forename: Frank M
authors.initials: FM
authors.lastname: van Bockxmeer
mesh_terms: D001055:Apolipoproteins B / Q000235:genetics*; D015415:Biomarkers / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004252:DNA Mutational Analysis; D030541:Databases, Genetic; D020440:Gene Duplication; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000379:methods*; D006579:Heterozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000453:epidemiology / Q000235:genetics*; D007438:Introns; D009154:Mutation; D010641:Phenotype; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000235:genetics*; D022821:RNA Splice Sites; D011973:Receptors, LDL / Q000235:genetics*; D017384:Sequence Deletion; D012697:Serine Endopeptidases / Q000235:genetics*; D014904:Western Australia / Q000453:epidemiology
chemical_list: D001055:Apolipoproteins B; D015415:Biomarkers; D008078:Cholesterol, LDL; C573412:LDLR protein, human; D022821:RNA Splice Sites; D011973:Receptors, LDL; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases